Pharming Group Shares Surge 11.33% at Thursday's Close
Pharming Group shares closed Thursday, January 22, at 1.69 euros, marking a remarkable surge of 11.33% from the previous day. This spike occurred as the Dutch laboratory specializing in rare diseases unveiled a higher-than-expected 2025 revenue of approximately $376 million, surpassing the revised range of $365 to $375 million announced in November, representing about a 27% growth from 2024. This strong performance reflects the continued growth of RUCONEST and the increasing demand for Joenja, mainly driven by patient adoption in the United States. The group will host a virtual investor day on February 3, 2026, to present its financial outlook and update on its clinical portfolio.
Recent Performance and Regulatory Milestones
Over the past seven days, the share price has increased by 7.51% and has recorded a rise of 45.06% over three months, demonstrating sustained upward momentum. Pharming Group is approaching a significant regulatory deadline. The U.S. FDA is expected to make its decision on extending leniolisib to children aged 4 to 11 with APDS syndrome by January 31, 2026. Currently, there are no approved treatments for children under 12 with this rare primary immunodeficiency. This potential approval would represent a significant market expansion for the drug, which has been authorized since March 2023 for patients aged 12 and older.
Technical Analysis and Market Sensitivity
From a technical perspective, the share price is now significantly above its key moving averages. The price of 1.69 euros is 15.75% above the 50-day moving average set at 1.46 euros, and exceeds the 200-day moving average of 1.25 euros by 35.20%. This setup indicates a well-established bullish orientation in the medium and long term. The breach of the resistance level at 1.61 euros is an additional positive technical signal, potentially paving the way for new highs. The RSI indicator stands at 58 points, operating in a neutral zone that leaves room for progression before reaching overbought levels around 70. This situation suggests that the bullish movement still has room to continue without immediate signs of fatigue. The one-month volatility is at 12.79%, while a beta of 0.49 indicates that the stock has moderate sensitivity to market movements. Over one year, the performance reaches 89.89%, placing Pharming Group among the most successful companies in the European biopharmaceutical sector.
